Toll Free: 1-888-928-9744
Published: Jun, 2015 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Radiodermatitis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Radiodermatitis - Pipeline Review, H1 2015', provides an overview of the Radiodermatitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Radiodermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiodermatitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Radiodermatitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Radiodermatitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Radiodermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Radiodermatitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiodermatitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Radiodermatitis Overview 6 Therapeutics Development 7 Pipeline Products for Radiodermatitis - Overview 7 Pipeline Products for Radiodermatitis - Comparative Analysis 8 Radiodermatitis - Therapeutics under Development by Companies 9 Radiodermatitis - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Radiodermatitis - Products under Development by Companies 12 Radiodermatitis - Companies Involved in Therapeutics Development 13 APEIRON Biologics AG 13 ProCertus BioPharm Inc. 14 Reata Pharmaceuticals, Inc. 15 Stemnion, Inc 16 Vida Therapeutics Inc. 17 Radiodermatitis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 Amnion Derived Cellular Cytokine Solution - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 APN-201 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PrC-210 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 RTA-408 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 VTI-1000 Series - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Radiodermatitis - Recent Pipeline Updates 36 Radiodermatitis - Dormant Projects 38 Radiodermatitis - Discontinued Products 39 Radiodermatitis - Product Development Milestones 40 Featured News & Press Releases 40 Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 40 Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 40 Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 41 Mar 05, 2013: Apeiron Biologics's Liposomal Formulation Of Recombinant Superoxide Dismutase Achieves All Endpoints In Clinical Study 41 Aug 22, 2012: Apeiron Biologics Receives €510,000 ZIT Grant For Further Development Of APN201 Project 42 Feb 27, 2012: Apeiron Initiates Clinical Study To Investigate Prevention Of Radiation-Induced Skin Damage In Breast Cancer Patients 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for Radiodermatitis, H1 2015 7 Number of Products under Development for Radiodermatitis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Radiodermatitis - Pipeline by APEIRON Biologics AG, H1 2015 13 Radiodermatitis - Pipeline by ProCertus BioPharm Inc., H1 2015 14 Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H1 2015 15 Radiodermatitis - Pipeline by Stemnion, Inc, H1 2015 16 Radiodermatitis - Pipeline by Vida Therapeutics Inc., H1 2015 17 Assessment by Monotherapy Products, H1 2015 18 Number of Products by Stage and Target, H1 2015 20 Number of Products by Stage and Mechanism of Action, H1 2015 22 Number of Products by Stage and Route of Administration, H1 2015 24 Number of Products by Stage and Molecule Type, H1 2015 26 Radiodermatitis Therapeutics - Recent Pipeline Updates, H1 2015 36 Radiodermatitis - Dormant Projects, H1 2015 38 Radiodermatitis - Discontinued Products, H1 2015 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.